vs
Side-by-side financial comparison of Community Healthcare Trust Inc (CHCT) and Cue Biopharma, Inc. (CUE). Click either name above to swap in a different company.
Community Healthcare Trust Inc is the larger business by last-quarter revenue ($31.5M vs $21.9M, roughly 1.4× Cue Biopharma, Inc.). Community Healthcare Trust Inc runs the higher net margin — 8.1% vs 7.2%, a 0.9% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 4.8%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 7.0%).
Medical Properties Trust, Inc. (MPT) is an international real estate investment trust (REIT) based in Birmingham, Alabama that purchases and invests in healthcare facilities and for-profit healthcare holding companies, primarily in the United States and Europe. Their property acquisitions often come in the form of sale-leaseback agreements, in which the original property owner sells the property to MPT and becomes their tenant. MPT's tenants are generally subject to long-term triple net lease...
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
CHCT vs CUE — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $31.5M | $21.9M |
| Net Profit | $2.5M | $1.6M |
| Gross Margin | — | — |
| Operating Margin | — | 9.0% |
| Net Margin | 8.1% | 7.2% |
| Revenue YoY | 4.8% | 1292.3% |
| Net Profit YoY | 60.2% | 116.7% |
| EPS (diluted) | — | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $31.5M | — | ||
| Q4 25 | $30.9M | $21.9M | ||
| Q3 25 | $31.1M | $2.1M | ||
| Q2 25 | $29.1M | $3.0M | ||
| Q1 25 | $30.1M | $421.0K | ||
| Q4 24 | $29.3M | $1.6M | ||
| Q3 24 | $29.6M | $3.3M | ||
| Q2 24 | $27.5M | $2.7M |
| Q1 26 | $2.5M | — | ||
| Q4 25 | $14.4M | $1.6M | ||
| Q3 25 | $1.6M | $-7.4M | ||
| Q2 25 | $-12.6M | $-8.5M | ||
| Q1 25 | $1.6M | $-12.3M | ||
| Q4 24 | $1.8M | — | ||
| Q3 24 | $1.7M | $-8.7M | ||
| Q2 24 | $-10.4M | $-10.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | 9.0% | ||
| Q3 25 | — | -353.4% | ||
| Q2 25 | — | -292.3% | ||
| Q1 25 | — | -2921.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -264.2% | ||
| Q2 24 | — | -390.6% |
| Q1 26 | 8.1% | — | ||
| Q4 25 | 46.6% | 7.2% | ||
| Q3 25 | 5.3% | -346.6% | ||
| Q2 25 | -43.2% | -287.1% | ||
| Q1 25 | 5.3% | -2911.4% | ||
| Q4 24 | 6.3% | — | ||
| Q3 24 | 5.9% | -259.6% | ||
| Q2 24 | -37.9% | -382.7% |
| Q1 26 | — | — | ||
| Q4 25 | $0.52 | $0.05 | ||
| Q3 25 | $0.03 | $-0.07 | ||
| Q2 25 | $-0.50 | $-0.09 | ||
| Q1 25 | $0.03 | $-0.17 | ||
| Q4 24 | $0.04 | — | ||
| Q3 24 | $0.04 | $-0.17 | ||
| Q2 24 | $-0.42 | $-0.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.6M | $27.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $421.3M | $26.4M |
| Total Assets | $1.0B | $42.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $2.6M | — | ||
| Q4 25 | $3.3M | $27.1M | ||
| Q3 25 | $3.4M | $11.7M | ||
| Q2 25 | $4.9M | $27.5M | ||
| Q1 25 | $2.3M | $13.1M | ||
| Q4 24 | $4.4M | $22.5M | ||
| Q3 24 | $2.8M | $32.4M | ||
| Q2 24 | $734.0K | $30.0M |
| Q1 26 | — | — | ||
| Q4 25 | $532.2M | — | ||
| Q3 25 | $530.1M | — | ||
| Q2 25 | $500.1M | — | ||
| Q1 25 | $496.0M | — | ||
| Q4 24 | $486.0M | — | ||
| Q3 24 | $473.7M | $1.0M | ||
| Q2 24 | $457.6M | $2.0M |
| Q1 26 | $421.3M | — | ||
| Q4 25 | $429.4M | $26.4M | ||
| Q3 25 | $426.8M | $13.2M | ||
| Q2 25 | $437.8M | $18.2M | ||
| Q1 25 | $461.3M | $6.6M | ||
| Q4 24 | $476.0M | $17.5M | ||
| Q3 24 | $477.2M | $25.4M | ||
| Q2 24 | $497.8M | $21.6M |
| Q1 26 | $1.0B | — | ||
| Q4 25 | $990.8M | $42.2M | ||
| Q3 25 | $987.3M | $31.6M | ||
| Q2 25 | $966.3M | $40.7M | ||
| Q1 25 | $985.1M | $22.3M | ||
| Q4 24 | $992.6M | $32.2M | ||
| Q3 24 | $981.8M | $44.8M | ||
| Q2 24 | $983.2M | $42.3M |
| Q1 26 | — | — | ||
| Q4 25 | 1.24× | — | ||
| Q3 25 | 1.24× | — | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 1.02× | — | ||
| Q3 24 | 0.99× | 0.04× | ||
| Q2 24 | 0.92× | 0.09× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-1.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | -0.68× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $56.4M | $-1.1M | ||
| Q3 25 | $12.7M | $-9.0M | ||
| Q2 25 | $13.8M | $-3.4M | ||
| Q1 25 | $14.4M | $-8.2M | ||
| Q4 24 | $58.9M | $-36.3M | ||
| Q3 24 | $13.8M | $-7.5M | ||
| Q2 24 | $16.7M | $-10.0M |
| Q1 26 | — | — | ||
| Q4 25 | $35.9M | — | ||
| Q3 25 | $7.6M | — | ||
| Q2 25 | $9.6M | $-3.4M | ||
| Q1 25 | $9.7M | $-8.3M | ||
| Q4 24 | $34.2M | $-36.4M | ||
| Q3 24 | $6.7M | $-7.5M | ||
| Q2 24 | $9.5M | $-10.0M |
| Q1 26 | — | — | ||
| Q4 25 | 116.0% | — | ||
| Q3 25 | 24.6% | — | ||
| Q2 25 | 32.9% | -116.5% | ||
| Q1 25 | 32.3% | -1976.7% | ||
| Q4 24 | 116.9% | -2309.3% | ||
| Q3 24 | 22.5% | -225.7% | ||
| Q2 24 | 34.7% | -376.2% |
| Q1 26 | — | — | ||
| Q4 25 | 66.3% | 0.0% | ||
| Q3 25 | 16.3% | 0.0% | ||
| Q2 25 | 14.5% | 0.9% | ||
| Q1 25 | 15.6% | 35.6% | ||
| Q4 24 | 84.1% | 4.2% | ||
| Q3 24 | 24.2% | 0.0% | ||
| Q2 24 | 26.1% | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | 3.91× | -0.68× | ||
| Q3 25 | 7.76× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 9.06× | — | ||
| Q4 24 | 32.14× | — | ||
| Q3 24 | 7.92× | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CHCT
Segment breakdown not available.
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
